ONCOSIL MEDICAL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.006 AUD | -14.29% |
|
0.00% | -33.33% |
| Apr. 16 | OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device | MT |
| Apr. 12 | OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study | MT |
| Sales 2022 | 1.06M 685K | Sales 2023 | 1.47M 946K | Capitalization | 23.71M 15.28M |
|---|---|---|---|---|---|
| Net income 2022 | -10M -6.44M | Net income 2023 | -11M -7.09M | EV / Sales 2022 | 27 x |
| Net cash position 2022 | 10.98M 7.07M | Net cash position 2023 | 9.22M 5.94M | EV / Sales 2023 | 9.87 x |
| P/E ratio 2022 |
-3.02
x | P/E ratio 2023 |
-1.2
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 55.27% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -14.29% | ||
| Current month | +20.00% | ||
| 1 month | -14.29% | ||
| 3 months | -25.00% | ||
| 6 months | -25.00% | ||
| Current year | -33.33% |
1 week
0.01
0.01
1 month
0.010.01
Current year
0.010.01
1 year
0.010.02
3 years
0.010.11
5 years
0.010.22
10 years
0.010.28
| Managers | Title | Age | Since |
|---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 20-05-03 |
Christian Cin
DFI | Director of Finance/CFO | - | 23-05-31 |
Jon Bell
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nigel Lange
CEO | Chief Executive Officer | - | 20-05-03 |
Douglas Cubbin
CHM | Chairman | - | 23-08-06 |
| Director/Board Member | - | 23-07-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 0.006 | -14.29% | 10 777 395 |
| 24-04-17 | 0.007 | 0.00% | 1,080,830 |
| 24-04-16 | 0.007 | 0.00% | 355,639 |
| 24-04-15 | 0.007 | +16.67% | 6,571,232 |
| 24-04-12 | 0.006 | 0.00% | 10,807,190 |
Delayed Quote Australian S.E., April 18, 2024 at 01:19 am EDT
More quotes
OncoSil Medical Ltd is an Australia-based medical device company seeking to advance radiation for cancer patients. The Company is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patientâs pancreatic tumors through an endoscopic ultrasound. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous-32 microparticles suspended in a specially formulated diluent. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.33% | 10.14M | |
| +28.79% | 676B | |
| +24.81% | 554B | |
| -7.64% | 349B | |
| +15.00% | 318B | |
| +5.99% | 291B | |
| +2.47% | 210B | |
| -0.02% | 204B | |
| -9.98% | 194B | |
| -11.71% | 144B |
- Stock Market
- Equities
- OSL Stock
